Journal ArticleDOI
Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid
Marco Carbone,George F. Mells,Greta Pells,Muhammad F. Dawwas,Julia L. Newton,Michael A. Heneghan,James Neuberger,Darren B. Day,Samantha J. Ducker,Richard Sandford,Graeme J.M. Alexander,David Jones,David Jones +12 more
Reads0
Chats0
TLDR
Among patients with PBC, response to UDCA, treatment and symptoms are related to sex and age at presentation, with the lowest response rates and highest levels of symptoms in women presenting at younger than age 50.About:
This article is published in Gastroenterology.The article was published on 2013-03-01. It has received 324 citations till now. The article focuses on the topics: Ursodeoxycholic acid & Cohort.read more
Citations
More filters
Journal ArticleDOI
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
Gideon M. Hirschfield,Ulrich Beuers,Christophe Corpechot,Pietro Invernizzi,David Jones,Marco Marzioni,Christoph Schramm +6 more
TL;DR: These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.
Journal ArticleDOI
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Frederik Nevens,Pietro Andreone,Giuseppe Mazzella,Simone I. Strasser,Christopher L. Bowlus,Pietro Invernizzi,J.P.H. Drenth,Paul J. Pockros,Jaroslaw Regula,Ulrich Beuers,Michael Trauner,David Jones,Annarosa Floreani,Simon Hohenester,Velimir A. Luketic,Mitchell L. Shiffman,K.J. van Erpecum,Victor Vargas,Catherine Vincent,Gideon M. Hirschfield,Hemant Shah,Bettina E. Hansen,Keith D. Lindor,Hanns-Ulrich Marschall,Kris V. Kowdley,R. Hooshmand-Rad,T. Marmon,S. Sheeron,R. Pencek,Leigh MacConell,Mark Pruzanski,David Shapiro +31 more
TL;DR: Obeticholic acid administered with ursodiol or as monotherapy for 12 months in patients with primary biliary cholangitis resulted in decreases from baseline in alkaline phosphatase and total bilirubin levels that differed significantly from the changes observed with placebo.
Journal ArticleDOI
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid
Gideon M. Hirschfield,Andrew Mason,Velimir A. Luketic,Velimir A. Luketic,Keith D. Lindor,Keith D. Lindor,Stuart C. Gordon,Marlyn J. Mayo,Kris V. Kowdley,Catherine Vincent,Henry C. Bodhenheimer,Henry C. Bodhenheimer,Albert Parés,Michael Trauner,Hanns-Ulrich Marschall,Luciano Adorini,Cathi Sciacca,Tessa Beecher-Jones,E. Castelloe,O. Bohm,David Shapiro +20 more
TL;DR: Daily doses of OCA significantly reduced levels of ALP, γ-glutamyl transpeptidase, and alanine aminotransferase, compared with placebo, in patients with primary biliary cirrhosis who had inadequate responses to ursodeoxycholic acid.
Journal ArticleDOI
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study
Willem J Lammers,Henk R. van Buuren,Gideon M. Hirschfield,Harry L.A. Janssen,Pietro Invernizzi,Andrew Mason,Cyriel Y. Ponsioen,Annarosa Floreani,Christophe Corpechot,Marlyn J. Mayo,Pier Maria Battezzati,Albert Parés,Frederik Nevens,Andrew K. Burroughs,Kris V. Kowdley,Palak J. Trivedi,Teru Kumagi,Teru Kumagi,Angela M. Cheung,Ana Lleo,Mohamad Imam,Kirsten Boonstra,Nora Cazzagon,I. Franceschet,Raoul Poupon,Llorenç Caballería,G. Pieri,Pushpjeet Kanwar,Keith D. Lindor,Keith D. Lindor,Bettina E. Hansen +30 more
TL;DR: Levels of alkaline phosphatase and bilirubin can predict outcomes (liver transplantation or death) of patients with PBC and might be used as surrogate end points in therapy trials.
Journal ArticleDOI
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
Christophe Corpechot,Olivier Chazouillères,Alexandra Rousseau,Antonia Le Gruyer,François Habersetzer,Philippe Mathurin,Odile Goria,Pascal Potier,Anne Minello,Christine Silvain,Armand Abergel,Maryline Debette-Gratien,Dominique Larrey,Olivier Roux,Jean-Pierre Bronowicki,Jérôme Boursier,Victor de Ledinghen,Alexandra Heurgué-Berlot,Eric Nguyen-Khac,Fabien Zoulim,Isabelle Ollivier-Hourmand,Jean-Pierre Zarski,Gisèle N'Kontchou,Sara Lemoinne,Lydie Humbert,Dominique Rainteau,Guillaume Lefèvre,Luc de Chaisemartin,Sylvie Chollet-Martin,Farid Gaouar,Farid-Hakeem Admane,Tabassome Simon,Raoul Poupon +32 more
TL;DR: Treating patients with primary biliary cholangitis with bezafibrate in addition to ursodeoxycholic acid resulted in a rate of complete biochemical response that was significantly higher than the rate with placebo and ursodespecific acid therapy.
References
More filters
Journal ArticleDOI
Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid
TL;DR: Biochemical response to UDCA after 1 year is associated with a similar survival to the matched control population, clearly supporting the favorable effects of this treatment in PBC.
Journal ArticleDOI
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Christophe Corpechot,Ludovico Abenavoli,Nabila Rabahi,Yves Chrétien,Tony Andreani,Catherine Johanet,Olivier Chazouillères,Raoul Poupon +7 more
TL;DR: This study defines the best efficient biochemical response to UDCA, which, independent of baseline predictive factors, identifies patients with PBC with a good long‐term prognosis and patients who fail to achieve this response and those with interface hepatitis or advanced histological stage should be targeted for further therapeutic research.
Journal ArticleDOI
Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis
George F. Mells,James A B Floyd,Katherine I. Morley,Katherine I. Morley,Heather J. Cordell,Christopher S. Franklin,So-Youn Shin,Michael A. Heneghan,James Neuberger,Peter T. Donaldson,Darren B. Day,Samantha J. Ducker,Agnes Muriithi,Elizabeth F Wheater,Christopher J Hammond,Muhammad F. Dawwas,David Jones,Leena Peltonen,Graeme J.M. Alexander,Richard Sandford,Carl A. Anderson +20 more
TL;DR: This study carried out a genome-wide association study (GWAS) using 1,840 cases from the UK PBC Consortium and 5,163 UK population controls as part of theWTCCC3 to identify additional loci, and identified 12 new susceptibility loci and three further new loci in a meta-analysis of data from this study and previously published GWAS results.
Journal ArticleDOI
Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid
Edith M.M. Kuiper,Bettina E. Hansen,Richard A. de Vries,Jannie W. den Ouden Muller,Theo J.M. van Ditzhuijsen,E. B. Haagsma,M. H. M. G. Houben,Ben J.M. Witteman,Karel J. van Erpecum,Henk R. van Buuren +9 more
TL;DR: Prognosis for UDCA-treated patients with early PBC is comparable to that of the general population and survival of those with advanced PBC with biochemical response to UDCA is significantly better than for nonresponders.
Journal ArticleDOI
Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
TL;DR: This study defines the best efficient biochemical response to UDCA that identifies patients with early PBC at very low risk of long-term development of liver failure or cirrhosis.